TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare joint tumor in early trial
Disease control OngoingThis study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC